Gilead Sciences

GILD Healthcare & Pharma 2/10 Low Risk
2/10
— 3 → 2 over 12 weeks
Sector avg: 2.9/10
▼
Risk Score Decreased
3/10 → 2/10

Score changed by 1 point as of 2026-05-25.

What changed
▼ Near-term maturity concentration: 11.3% → 5.9% (improved)
▼ Cash coverage: 1.93x → 4.12x (improved)

Gilead Sciences carries $22.2B in long-term debt, with $22.2B in scheduled principal maturities. DebtCanary scores GILD at 2/10, suggesting manageable refinancing risk.

Maturity Schedule

As of 2026-03-31 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.
Year 1 $1.3B Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $0 Beyond 5 $20.9B
Period Amount Due % of Total
Year 1 (0-12 months) $1.3B 5.9%
Year 2 (12-24 months) N/A N/A
Year 3 (24-36 months) N/A N/A
Year 4 (36-48 months) N/A N/A
Year 5 (48-60 months) N/A N/A
Beyond 5 Years $20.9B 94.1%
Total Scheduled Maturities $22.2B 100.0%

Key Metrics

Total Long-Term Debt
$22.2B
Near-Term (12mo)
$1.3B
Interest Coverage
10.6x
Debt/Equity
0.94
Cash Coverage
4.12x
Operating Income
$10.0B

Score Components

Component Value Weight
Near-Term Maturity Concentration 5.9% 30%
Interest Coverage Ratio 10.6x 25%
Debt-to-Equity Ratio 0.94 25%
Cash Coverage of Near-Term Debt 4.12x 20%

Recent SEC Filings

Material disclosures from Gilead Sciences's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date Form Details
2026-05-20 8-K Material Agreement, New Debt Obligation, Other Events
2026-05-18 424B5 Prospectus supplement — possible debt or equity issuance
2026-05-14 424B5 Prospectus supplement — possible debt or equity issuance
2026-05-07 10-Q Quarterly report
2026-05-07 8-K Earnings Results
2026-05-04 8-K Shareholder Vote
2026-04-28 8-K Reg FD Disclosure, Other Events
2026-03-20 DEFA14A Additional proxy materials

Related Companies

Johnson & Johnson
JNJ
2/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
5/10
Debt: N/A 12mo: $3.9B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
3/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
2/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.1B 12mo: $2.0B
Amgen
AMGN
5/10
Debt: $57.3B 12mo: $4.6B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-31. Filing date: 2026-05-07. Data last fetched: 2026-05-25. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.
View SEC EDGAR filings for Gilead Sciences →